O	0	6	Weekly
B-intervention	7	17	paclitaxel
O	18	26	improves
O	27	37	pathologic
O	38	46	complete
O	47	56	remission
O	57	59	in
O	60	68	operable
O	69	75	breast
O	76	82	cancer
O	83	87	when
O	88	96	compared
O	97	101	with
O	102	112	paclitaxel
O	113	117	once
O	118	123	every
O	124	125	3
O	126	131	weeks
O	131	132	.

O	133	135	To
O	136	145	determine
O	146	149	the
O	150	156	impact
O	157	158	a
O	159	165	change
O	166	168	in
O	169	177	schedule
O	178	180	of
O	181	191	paclitaxel
O	192	206	administration
O	207	211	from
O	212	216	once
O	217	222	every
O	223	224	3
O	225	230	weeks
O	231	233	to
O	234	242	frequent
O	243	257	administration
O	258	263	would
O	264	268	have
O	269	271	on
O	272	275	the
O	276	286	pathologic
O	287	295	complete
O	296	304	response
O	305	306	(
O	306	309	pCR
O	309	310	)
O	311	315	rate
O	316	318	in
O	319	322	the
O	323	329	breast
O	330	333	and
O	334	339	lymph
O	340	345	nodes
O	346	349	for
O	350	358	patients
O	359	363	with
O	364	372	invasive
O	373	379	breast
O	380	386	cancer
O	387	394	treated
O	395	399	with
O	400	407	primary
O	408	416	systemic
O	417	429	chemotherapy
O	430	431	(
O	431	434	PST
O	434	435	)
O	435	436	.

B-eligibility	437	445	Patients
I-eligibility	446	450	with
I-eligibility	451	459	clinical
I-eligibility	460	465	stage
I-eligibility	466	467	I
I-eligibility	467	468	-
I-eligibility	468	472	IIIA
I-eligibility	473	479	breast
I-eligibility	480	486	cancer
O	487	491	were
O	492	500	randomly
O	501	509	assigned
O	510	512	to
O	513	520	receive
O	521	524	PST
O	525	527	of
O	528	538	paclitaxel
O	539	544	doses
O	545	557	administered
O	558	564	either
O	565	571	weekly
O	572	573	(
O	573	576	for
O	577	578	a
O	579	584	total
O	585	587	of
O	588	590	12
O	591	596	doses
O	597	599	of
O	600	610	paclitaxel
O	610	611	)
O	612	614	or
O	615	619	once
O	620	625	every
O	626	627	3
O	628	633	weeks
O	634	635	(
O	635	639	four
O	640	646	cycles
O	646	647	)
O	647	648	,
O	649	657	followed
O	658	660	by
O	661	665	four
O	666	672	cycles
O	673	675	of
O	676	688	fluorouracil
O	688	689	/
O	689	700	doxorubicin
O	700	701	/
O	701	717	cyclophosphamide
O	718	719	(
O	719	722	FAC
O	722	723	)
O	724	726	in
B-control	727	735	standard
I-control	736	741	doses
O	742	747	every
O	748	749	3
O	750	755	weeks
O	755	756	.

O	757	760	Two
O	761	770	different
O	771	776	doses
O	777	779	of
O	780	790	paclitaxel
O	791	795	were
O	796	800	used
O	801	806	based
O	807	809	on
O	810	815	lymph
O	816	820	node
O	821	827	status
O	828	835	defined
O	836	838	by
O	839	849	ultrasound
O	850	853	and
O	854	858	fine
O	859	865	needle
O	866	876	aspiration
O	876	877	.

O	878	886	Clinical
O	887	895	response
O	896	899	and
O	900	906	extent
O	907	909	of
O	910	918	residual
O	919	926	disease
O	927	929	in
O	930	933	the
O	934	940	breast
O	941	944	and
O	945	950	lymph
O	951	956	nodes
O	957	960	was
O	961	969	assessed
O	970	975	after
O	976	986	completion
O	987	989	of
O	990	993	all
O	994	1006	chemotherapy
O	1006	1007	.

O	1008	1009	A
O	1010	1015	total
O	1016	1018	of
B-total-participants	1019	1022	258
O	1023	1031	patients
O	1032	1036	were
O	1037	1045	randomly
O	1046	1054	assigned
O	1055	1057	to
O	1058	1065	receive
O	1066	1071	doses
O	1072	1074	of
O	1075	1085	paclitaxel
O	1086	1098	administered
O	1099	1105	either
O	1106	1112	weekly
O	1113	1115	or
O	1116	1120	once
O	1121	1126	every
O	1127	1128	3
O	1129	1134	weeks
O	1134	1135	,
O	1136	1144	followed
O	1145	1147	by
O	1148	1151	FAC
O	1151	1152	.

O	1153	1155	Of
O	1156	1161	these
B-total-participants	1162	1165	258
O	1166	1174	patients
O	1174	1175	,
B-total-participants	1176	1179	110
O	1180	1188	patients
O	1189	1192	had
O	1193	1203	histologic
O	1204	1209	lymph
O	1210	1214	node
O	1215	1226	involvement
O	1227	1230	and
B-total-participants	1231	1234	148
O	1235	1243	patients
O	1244	1247	had
O	1248	1256	clinical
O	1257	1259	N0
O	1260	1267	disease
O	1267	1268	.

O	1269	1275	Weekly
O	1276	1286	paclitaxel
O	1287	1295	followed
O	1296	1298	by
O	1299	1302	FAC
O	1303	1306	was
O	1307	1319	administered
O	1320	1322	to
B-intervention-participants	1323	1326	127
O	1327	1335	patients
O	1336	1339	and
O	1340	1344	once
O	1344	1345	-
O	1345	1350	every
O	1350	1351	-
O	1351	1352	3
O	1352	1353	-
O	1353	1358	weeks
O	1359	1369	paclitaxel
O	1370	1378	followed
O	1379	1381	by
O	1382	1385	FAC
O	1386	1389	was
O	1390	1402	administered
O	1403	1405	to
B-control-participants	1406	1409	131
O	1410	1418	patients
O	1418	1419	.

B-outcome	1420	1428	Clinical
I-outcome	1429	1437	response
O	1438	1440	to
O	1441	1450	treatment
O	1451	1454	was
O	1455	1462	similar
O	1463	1470	between
O	1471	1477	groups
O	1478	1479	(
O	1479	1480	P
O	1481	1482	=
O	1483	1484	.
O	1484	1486	25
O	1486	1487	)
O	1487	1488	.

O	1489	1497	Patients
O	1498	1507	receiving
O	1508	1514	weekly
O	1515	1525	paclitaxel
O	1526	1529	had
O	1530	1531	a
O	1532	1538	higher
B-outcome	1539	1542	pCR
I-outcome	1543	1547	rate
O	1548	1549	(
B-iv-bin-percent	1549	1551	28
I-iv-bin-percent	1551	1552	.
I-iv-bin-percent	1552	1553	2
I-iv-bin-percent	1553	1554	%
O	1554	1555	)
O	1556	1560	than
O	1561	1569	patients
O	1570	1577	treated
O	1578	1582	with
O	1583	1587	once
O	1587	1588	-
O	1588	1593	every
O	1593	1594	-
O	1594	1595	3
O	1595	1596	-
O	1596	1601	weeks
O	1602	1612	paclitaxel
O	1613	1614	(
B-cv-bin-percent	1614	1616	15
I-cv-bin-percent	1616	1617	.
I-cv-bin-percent	1617	1618	7
I-cv-bin-percent	1618	1619	%
O	1619	1620	;
O	1621	1622	P
O	1623	1624	=
O	1625	1626	.
O	1626	1628	02
O	1628	1629	)
O	1629	1630	,
O	1631	1635	with
O	1636	1644	improved
B-outcome	1645	1651	breast
I-outcome	1652	1664	conservation
I-outcome	1665	1670	rates
O	1671	1672	(
O	1672	1673	P
O	1674	1675	=
O	1676	1677	.
O	1677	1679	05
O	1679	1680	)
O	1680	1681	.

O	1682	1685	The
O	1686	1692	change
O	1693	1695	in
O	1696	1704	schedule
O	1705	1707	of
O	1708	1718	paclitaxel
O	1719	1723	from
O	1724	1728	once
O	1729	1734	every
O	1735	1736	3
O	1737	1742	weeks
O	1743	1745	to
O	1746	1747	a
O	1748	1752	more
O	1753	1761	frequent
O	1762	1776	administration
O	1777	1790	significantly
O	1791	1799	improved
O	1800	1803	the
O	1804	1811	ability
O	1812	1814	to
O	1815	1824	eradicate
O	1825	1833	invasive
O	1834	1840	cancer
O	1841	1843	in
O	1844	1847	the
O	1848	1854	breast
O	1855	1858	and
O	1859	1864	lymph
O	1865	1870	nodes
O	1870	1871	.
